Glucagon-Like Peptide I (7-36), amide, human

Glucagon-Like Peptide I (7-36), amide, human

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2

30

95.9%

C₁₄₉H₂₂₆N₄₀O₄₅

3297.68

Synthetic

Powder

This GLP-1 fragment is secreted from the lower small intestine and shows a strong insulinotropic effect. GLP-1 (7-36) amide is considered as the most important incretin hormone. Its action is mediated by receptors expressed by the endocrine pancreatic B-cells. Considerable interest has focused on the development of this peptide as a therapeutic strategy for non-insulin-dependent (type 2 ) diabetes mellitus and associated neuropathy.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• G.I.Bell et al., Nature, 304, 368 (1983)
• B.Kreymann et al., Lancet, 2, 1300 (1987)
• C.Orskov and J.H.Nielsen, FEBS Lett., 229, 175 (1988)
• J.-P.Raufman et al., J. Biol. Chem., 267, 21432 (1992)
• P.A.Martin and A.Faulkner, Comp. Biochem. Biophys., 105A, 705 (1993)
• H.C.Fehmann et al., Peptides, 15, 453 (1994)
• M.A.Nauck et al., Exp. Clin. Endocrinol. Diabetes, 105, 187 (1997)

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.